CN117836284A - 治疗神经毒剂诱导的癫痫发作的方法 - Google Patents

治疗神经毒剂诱导的癫痫发作的方法 Download PDF

Info

Publication number
CN117836284A
CN117836284A CN202280052288.XA CN202280052288A CN117836284A CN 117836284 A CN117836284 A CN 117836284A CN 202280052288 A CN202280052288 A CN 202280052288A CN 117836284 A CN117836284 A CN 117836284A
Authority
CN
China
Prior art keywords
hours
pharmaceutically acceptable
benzodiazepine
prodrug
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052288.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·F·托姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronilas Co
Original Assignee
Pronilas Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronilas Co filed Critical Pronilas Co
Publication of CN117836284A publication Critical patent/CN117836284A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280052288.XA 2021-06-09 2022-06-09 治疗神经毒剂诱导的癫痫发作的方法 Pending CN117836284A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208885P 2021-06-09 2021-06-09
US63/208,885 2021-06-09
PCT/US2022/032783 WO2022261287A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Publications (1)

Publication Number Publication Date
CN117836284A true CN117836284A (zh) 2024-04-05

Family

ID=84425551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052288.XA Pending CN117836284A (zh) 2021-06-09 2022-06-09 治疗神经毒剂诱导的癫痫发作的方法

Country Status (10)

Country Link
US (1) US20240277696A1 (https=)
EP (1) EP4352047A4 (https=)
JP (1) JP2024521430A (https=)
KR (1) KR20240022544A (https=)
CN (1) CN117836284A (https=)
AU (1) AU2022291138A1 (https=)
CA (1) CA3222575A1 (https=)
IL (1) IL309097A (https=)
MX (1) MX2023014418A (https=)
WO (1) WO2022261287A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511741B1 (en) * 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US11045462B2 (en) * 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2018169798A1 (en) * 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
IL309097A (en) 2024-02-01
WO2022261287A1 (en) 2022-12-15
JP2024521430A (ja) 2024-05-31
KR20240022544A (ko) 2024-02-20
MX2023014418A (es) 2024-02-13
EP4352047A4 (en) 2025-04-16
EP4352047A1 (en) 2024-04-17
US20240277696A1 (en) 2024-08-22
AU2022291138A1 (en) 2023-12-07
CA3222575A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
AU2021229240B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN107249591B (zh) 固体药物配制品及其制备方法
DE69623899T2 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
JPH0317046A (ja) アリールオキシフエニルプロピルアミン、その製造方法及びその使用方法
EA012610B1 (ru) Аналоги локсапина и фармацевтические композиции на их основе
CN113698345B (zh) 作为钾通道调节剂的化合物及其制备和应用
CA3151863C (en) Compound as potassium channel regulator and preparation and use thereof
US20230390292A1 (en) Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
US12357632B2 (en) Methods of treating cholangiocarcinoma
JP5466510B2 (ja) シドノンイミン−特異的ドーパミン再摂取阻害剤およびそのドーパミン関連障害の治療における使用
KR20250171459A (ko) 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도
KR102015484B1 (ko) 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물
JP2002322092A (ja) Ｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）アンタゴニストの予防的使用
CN117836284A (zh) 治疗神经毒剂诱导的癫痫发作的方法
US3560619A (en) Aminoquinazolines and quinazolones in treatment of coccidiosis
KR100556559B1 (ko) 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도
HK40058596B (en) Compounds as potassium channel regulators and preparation and use thereof
HK40058596A (zh) 作为钾通道调节剂的化合物及其制备和应用
HK40068494A (en) Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
TW202124359A (zh) 用於增加磷酸化ampk蛋白含量之方法及材料
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination